# Biomea Fusion (BMEA) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/BMEA
## Company Profile
- Ticker: BMEA
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 1.25 USD
- Market cap: 99050232.80000001 USD
- Last updated: 2026-08-06
## Business Overview
### Metabolic Disease Company
Biomea Fusion develops small molecules intended to restore metabolic function in diabetes and obesity.
### Icovamenib
Icovamenib is a covalent menin inhibitor being evaluated for potential restoration of insulin-producing beta-cell function in type 1 and type 2 diabetes.
### COVALENT Program
COVALENT-211 and COVALENT-212 are Phase 2 studies in different type 2 diabetes populations.
### BMF-650
BMF-650 is an oral GLP-1 receptor agonist in early clinical development for obesity.
## Why The Stock Is Moving

The latest company update was “Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights”. BMEA changed 0.79% and closed at $1.25 on Aug 6, 2026, indicating a relatively limited closing-price reaction to this earnings update.

## Future Catalysts

- Initial 28-day weight-reduction data from the Phase 1 BMF-650 study are expected in the second quarter of 2026.
- Twenty-six-week topline data from COVALENT-211 and COVALENT-212 are expected in the fourth quarter of 2026.

## Drug Assets

- icovamenib

## Recent News
- 2026-08-05 20:05 EST — [Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/BMEA/biomea-fusion-reports-second-quarter-2026-financial-results-and-corporate-highli-c0417574) — Source: Biomea Fusion
- 2026-06-05 23:32 EST — [Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study](https://biopharmsignal.com/news/BMEA/biomea-fusion-presents-new-clinical-and-translational-data-for-icovamenib-at-the-82402558) — Source: Biomea Fusion
- 2026-06-03 12:00 EST — [Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity](https://biopharmsignal.com/news/BMEA/biomea-fusion-announces-research-collaboration-with-university-of-leicester-to-evaluate-icovamenib-in-combination-with-semaglutide-in-obesity) — Source: Biomea Fusion
- 2026-05-12 20:05 EST — [Biomea Fusion to Participate at Upcoming Investor Conferences](https://biopharmsignal.com/news/BMEA/biomea-fusion-to-participate-at-upcoming-investor-conferences-90b3eaa9) — Source: Biomea Fusion
- 2026-05-11 20:55 EST — [Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/BMEA/biomea-fusion-reports-first-quarter-2026-financial-results-and-corporate-highlights) — Source: Biomea Fusion